Clinical Scorecard: Patient Casebook Series: Ligneous Conjunctivitis -- Identifying and Treating a Rare Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Ligneous conjunctivitis due to plasminogen deficiency type 1 (PLGD-1) |
| Key Mechanisms | Systemic protein deficiency leading to ligneous lesions on mucosal membranes |
| Target Population | Patients with plasminogen deficiency type 1, often presenting in childhood |
| Care Setting | Ophthalmology and hematology clinics |
Key Highlights
- Ligneous conjunctivitis is the most common manifestation of PLGD-1, with 81% of patients affected.
- RYPLAZIM is the first FDA-approved treatment for PLGD-1, improving symptoms and preventing recurrence.
- Persistent pseudomembranous conjunctivitis suggests PLGD-1 and requires laboratory confirmation.
Guideline-Based Recommendations
Diagnosis
- Laboratory confirmation of plasminogen activity is necessary for diagnosing PLGD-1.
Management
- RYPLAZIM is indicated for the treatment of PLGD-1 to resolve lesions and prevent new ones.
Monitoring & Follow-up
- Monitor for bleeding and adverse reactions during and after RYPLAZIM infusion.
Risks
- Potential for bleeding, hypersensitivity reactions, and transmission of infectious agents with RYPLAZIM.
Patient & Prescribing Data
Patients diagnosed with plasminogen deficiency type 1, often with recurrent mucosal lesions.
RYPLAZIM has shown symptomatic improvement within 30 minutes of infusion.
Clinical Best Practices
- Ensure communication among care team members for comprehensive management of PLGD-1.
- Consider surgical excision for severe lesions, but recognize the need for systemic treatment to prevent recurrence.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.